Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2024 00:00 ET | Source: Angelini Pharma

Angelini Pharma stipula un accordo di opzione di licenza esclusiva con Cureverse per lo sviluppo e la commercializzazione a livello mondiale di una nuova e innovativa sostanza per la salute del cervello in fase clinica

L'accordo conferisce ad Angelini Pharma un'opzione di licenza esclusiva per lo sviluppo e la commercializzazione di CV-01, un nuovo composto in fase clinica 1 con un grande potenziale per il...
October 21, 2024 00:00 ET | Source: Angelini Pharma

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset

Angelini Pharma Enters Into Exclusive Option Agreement With Cureverse to License Global Development & Commercialization Rights For Brain Health Asset
July 28, 2021 07:00 ET | Source: Angelini Pharma

Angelini Pharma and Lumira Ventures launch the Angelini Lumira Biosciences Fund (ALBF)

Angelini Pharma and Lumira Ventures launch the Angelini Lumira Biosciences Fund (ALBF) - Angelini Pharma will invest US$35 million and be the sole investor in this innovative fund - ALBF will invest...
July 28, 2021 02:00 ET | Source: Angelini Pharma

Angelini Pharma and Lumira Ventures launch the Angelini Lumira Biosciences Fund (ALBF)

Angelini Pharma and Lumira Ventures launch the Angelini Lumira Biosciences Fund (ALBF) - Angelini Pharma will invest US$35 million and be the sole investor in this innovative fund - ALBF will invest...